Discovery of Novel, Potent and Long Acting CCK Analogs

Robert Hunter¹, Andrew Carpenter¹, Erin Swiger¹, Makda Mebrahtu¹, Robert Wiard¹, Andrea Acker¹, Shane Roller¹,², Mark Paulik¹,², and Ved Srivastava*¹,²

¹GlaxoSmithKline, 5 Moore Dr. Research Triangle Park, NC, 27709, USA; ²Phoundry Pharmaceuticals Inc., 6 Davis Dr., Research Triangle Park, NC, 27709, USA

Introduction

Cholecystokinin (CCK) is a sulfated neuropeptide hormone and neurotransmitter synthesized by cells in the mucosal epithelium of the small intestine and secreted in the duodenum. The C-terminal fragment CCK-8, inhibits gastric emptying as well as other physiological processes involved in satiety.

Results and Discussion

While the physiological effects of inhibiting gastric emptying, decreasing gastric acid secretion and satiety make CCK-8 an interesting peptide for the treatment of obesity, the anxiolytic effect which is normally attributed to the Cholecystokinin B receptor, complicate its use. In our research, we sought to synthesize a long acting peptide CCK agonist which was selective for the CCK-A receptor, had desired potency and sufficient solubility to be dosed using an implanted osmotic mini pump. To do this, we used much of the data which has been previously reported and attempted to systematically assemble it into a single peptide agonist with the desired pharmacokinetic profile.

- Potency in vitro (>9.5 pIC₅₀)
- 200 fold selectivity over CCK-B
- 45 min or better t½ (CCK-8 = 20 min)
- Equal or better food intake reduction than CCK-8
- Solubility >160 mg/mL

A screening of the literature provided the following information:
- Sulfation of Tyr27 is required for biological activity of the native peptide at the CCK-A receptor [1]
- Non hydrolyzable Sulfated Tyr27 mimetics are desired for synthetic ease, chemical stability [1]
- Activity is restored to non-sulfated CCK-4 when Met31 is replaced with a Lys(Tac) residue [2]
- Hexapeptide analogs retain potency when both Met28 and Met31 are replaced with norleucine [3]
- N-methyl-Phenylalanine enhances metabolic stability [4]
- N-terminal pGlu-Gln enhances metabolic stability [5]

The literature modifications were systematically incorporated, resulting in peptide 34 (Table 1) which had the desired potency, selectivity, food intake reduction and a solubility > 150 mg/mL. While endogenous CCK-8 lacks the selectivity duration of action and solubility to be used as an effective tool compound in combination studies, the introduction of modifications to the peptide sequence gleaned from the literature enabled us to generate a suitable molecule.

Table 1. Key analogs.

<table>
<thead>
<tr>
<th>ID</th>
<th>SEQUENCE</th>
<th>CCK A</th>
<th>CCK B</th>
<th>CCK Select, A/B</th>
<th>A.F.I. 6hr</th>
<th>A.F.I. 15hr</th>
<th>A.F.I. 30hr</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>D(Y-SO₃H)MGWMDF-NH₂ (CCK-8)</td>
<td>10.5</td>
<td>9.8</td>
<td>5</td>
<td>-59</td>
<td>-26</td>
<td>-10</td>
</tr>
<tr>
<td>33</td>
<td>(pGlu)KKKRD(F-CH₂SO₃H)LGW(K-Tac)D(mePhe)-NH₂</td>
<td>9.8</td>
<td>7.5</td>
<td>200</td>
<td>-91</td>
<td>-69</td>
<td>-48</td>
</tr>
<tr>
<td>34</td>
<td>(pGlu)KKKKKRD(F-CH₂SO₃H)LGW(K-Tac)D(mePhe)-NH₂</td>
<td>9.9</td>
<td>7.5</td>
<td>251</td>
<td>-100</td>
<td>-90</td>
<td>-68</td>
</tr>
<tr>
<td>35</td>
<td>(pGlu)KKKKKKRD(F-CH₂SO₃H)LGW-(K-Tac)D(mePhe)-NH₂</td>
<td>9.6</td>
<td>7</td>
<td>398</td>
<td>-100</td>
<td>-95</td>
<td>-73</td>
</tr>
</tbody>
</table>
The novel peptide 34 (Figure 1) demonstrated a pEC$_{50}$ of 9.9 and a duration of action greater than 60h in an acute DIO mouse model. The improvements to CCK-8 translate to an ED$_{50}$ 0.09 mg/kg/day and an observed weight loss of 23% when dosed in combination with Exendin-4 in the 14 day DIO rat model (Figure 2).

**Fig. 1. Peptide 34.**

**Fig. 2. In vivo results.**

**References**

4. Simmons, R.D., Blosser, J.C., Rosamond, J.R. *Pharmacology Biochemistry and Behavior* 47, 701-708 (1994), [http://dx.doi.org/10.1016/0091-3057(94)90176-7](http://dx.doi.org/10.1016/0091-3057(94)90176-7)
5. Irwin, N., Frizelle, P., Montgomery, I.A., Moffett, R.C., O’Harte, F.P.M., Flatt, P.R. *Diabetologia* 55, 2747-2758 (2012), [http://dx.doi.org/10.1007/s00125-012-2654-6](http://dx.doi.org/10.1007/s00125-012-2654-6)